Aramco reportedly in advanced talks with India's Reliance Industries on deal worth up to $25 billion

BioNTech Downtick Continues

BioNTech SE (BNTX) shares are sliding on Monday morning trade continuing a fall since August 13. There were no corporate announcements from the company today to impact the stock movement.

Currently, shares are trading $347.38, down 7.79 percent from the previous close of $377.32 on a volume of 443,868. For the 52-week period, the shares have traded in a range of $54.10-$464-00 on average volume of 3,565,704.

Mind Over Money: Share your story about what is keeping you up at night about your money

Tell us about the financial anxiety you're currently facing and submit a question for our financial experts. You may be considered to ask your question live during the Invest in You: Mind Over Money virtual event on September 9, 2021. Please be sure to include thoughtful detail.

Responses must be submitted no later than 11:59 pm ET on August 27, 2021.

By submitting your response, you are agreeing to CNBC's Terms of Use and Privacy Policy and opting in to receiving newsletters, updates, announcements, offers and general marketing emails from CNBC and other NBCUniversal businesses.

Additionally, by submitting your email address, you agree that you may be contacted by members of the CNBC editorial team.

For more about how Americans can make smarter decisions about how they save, spend, invest and protect their money, visit cnbc.com/invest-in-you.    

SIGN UP: Money 101 is an 8-week learning course to financial freedom, delivered weekly to your inbox.

CHECK OUT: How to make money with creative side hustles, from people who earn thousands on sites like Etsy and Twitch via Grow with Acorns+CNBC.

Disclosure: NBCUniversal and Comcast Ventures are investors in Acorns.

No homes available… What’s going on? Sellers rent to beat property shortage

We use your sign-up to provide content in ways you’ve consented to and to improve our understanding of you. This may include adverts from us and 3rd parties based on our understanding. You can unsubscribe at any time. More info

Growing numbers of sellers are renting because of a lack of properties to buy.

Some people making lifestyle changes are also “trying before they buy”, using short-term tenancies.

Sellers in Scotland, Wales and the NorthWest are most likely to rent. There, 16.4 percent, 15.3 percent and 11.8 percent respectively of new tenancies this year were to those who had sold up.

Looking for a new home, or just fancy a look? Add your postcode below or visit InYourArea

Having nowhere to sell may also help buyers to pounce on the right property.

But this trend means that in July there were 43 percent fewer homes available to rent than last year.

Aneisha Beveridge, head of research at Hamptons, said: “While moving into a rented home to beat the end of a stamp duty holiday is not new, it is increasingly being used as a stop-gap by house-hunters faced with a lack of stock to buy.”

CVAC Shares Up; CV2CoV Shows Improved Immune Response In Preclinical Study

Shares of CureVac N.V. (CVAC) are currently trading at $60.02, up $1.22 or 2.07%, with trading volume of over 518K versus an average volume of 1.27 million shares. The stock has been trading in the range of $43.00 – $151.80 for the past one year.

CureVac said its second-generation COVID-19 vaccine candidate, CV2CoV, is advancing on track to enter clinical development in fourth quarter, 2021. Also, the company remains committed to seeking regulatory approval with European Medicines agency for its first-generation COVID-19 vaccine candidate, CVnCoV.

CureVac and GSK published preclinical data, characterizing immune responses as well as the protective efficacy of CV2CoV and CVnCoV against SARS-CoV-2 challenge in non-human primates. Higher antibody neutralizing capacity was observed with CV2CoV across all selected variants, including the Beta, Delta and Lambda variants.

“In this animal model, CV2CoV is shown to induce broad antibody and cellular immune responses very similar to the breadth of the immune responses observed after infection with SARS-CoV-2,” said Igor Splawski, Chief Scientific Officer of CureVac.

Aramco reportedly in advanced talks with India's Reliance Industries on deal worth up to $25 billion

  • An agreement could be reached as soon as the coming weeks, according to the report, which cited people with knowledge of the matter.
  • Reliance announced a sale of a 20% stake in its oil-to-chemicals business to Aramco for $15 billion in 2019, but the deal stalled after oil prices and demand crashed last year due to the pandemic.

Saudi Aramco is in advanced talks to acquire a roughly 20% stake in Reliance Industries' oil refining and chemicals business for about $20 billion to $25 billion in Aramco's shares, Bloomberg News reported on Monday.

An agreement could be reached as soon as the coming weeks, according to the report, which cited people with knowledge of the matter.

Aramco and Reliance declined to comment.

Reliance announced a sale of a 20% stake in its oil-to-chemicals business to Aramco for $15 billion in 2019, but the deal stalled after oil prices and demand crashed last year due to the pandemic.

During Aramco's earnings briefing earlier in August, Chief Executive Officer Amin Nasser said the company was still doing due diligence on the deal.

In late June, Reliance's billionaire chairman Mukesh Ambani said it hopes to formalise its partnership with Aramco this year and its Chairman Yasir Al-Rumayyan will join the Indian conglomerate's board as an independent director.

Reliance shares were up 2% at 2,187.80 rupees on Monday.